Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF35700 PK in Hepatic Impairment
NCT03189615Phase 1Completed
- Sponsor
- Lundbeck
- Start
- May 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lu af35700 in schizophrenia (3 arms), sponsored by Lundbeck. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity and Maximum observed plasma concentration. Started May 2017; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03189615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189615.